Cited 0 times in
A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 노성훈 | - |
dc.contributor.author | 노재경 | - |
dc.contributor.author | 라선영 | - |
dc.contributor.author | 유내춘 | - |
dc.contributor.author | 임종근 | - |
dc.contributor.author | 정현철 | - |
dc.contributor.author | 정희철 | - |
dc.date.accessioned | 2015-05-19T16:38:14Z | - |
dc.date.available | 2015-05-19T16:38:14Z | - |
dc.date.issued | 2008 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/106668 | - |
dc.description.abstract | PURPOSE: The aim of this study was to investigate the efficacy and safety of the combination chemotherapy of paclitaxel, infusional 5-fluorouracil (5-FU) and leucovorin (FLT regimen) in advanced gastric cancer. The primary end point was the time to progression (TTP). METHODS: Patients with evaluable disease with or without measurable lesions received 175 mg/m2 paclitaxel on day 1 followed by 20 mg/m2 leucovorin and 24-h infusion of 5-FU 1,000 mg/m2 (day 1-3) repeated every 3 weeks. RESULTS: Sixty patients were enrolled. The median TTP and overall survival duration were 13 and 60 weeks, respectively. One-year survival rate was 53.3%. Of the 50 patients with measurable lesion, the overall response rate was 31.7%. The most common grade 3-4 adverse event was neutropenia (61.7%). CONCLUSION: The FLT regimen showed an efficacy comparable to other regimens of cisplatin or anthracycline combinations with the advantage of remarkably low non-hematological toxicity. These data about the efficacy of this regimen need confirmation in a phase III trial. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 315~321 | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antidotes/administration & dosage | - |
dc.subject.MESH | Antimetabolites, Antineoplastic/administration & dosage | - |
dc.subject.MESH | Antineoplastic Agents, Phytogenic/administration & dosage | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/administration & dosage | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/administration & dosage | - |
dc.subject.MESH | Hematologic Diseases/blood | - |
dc.subject.MESH | Hematologic Diseases/chemically induced | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Infusions, Intravenous | - |
dc.subject.MESH | Leucovorin/administration & dosage | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Metastasis | - |
dc.subject.MESH | Paclitaxel/administration & dosage | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Stomach Neoplasms/drug therapy* | - |
dc.subject.MESH | Survival Analysis | - |
dc.title | A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학) | - |
dc.contributor.googleauthor | Chong Kun Im | - |
dc.contributor.googleauthor | Hei-Cheul Jeung | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.contributor.googleauthor | Nae Choon Yoo | - |
dc.contributor.googleauthor | Sung Hoon Noh | - |
dc.contributor.googleauthor | Jae Kyung Roh | - |
dc.contributor.googleauthor | Hyun Cheol Chung | - |
dc.identifier.doi | 10.1007/s00280-007-0508-6 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01281 | - |
dc.contributor.localId | A01290 | - |
dc.contributor.localId | A02457 | - |
dc.contributor.localId | A03402 | - |
dc.contributor.localId | A03773 | - |
dc.contributor.localId | A03794 | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J00437 | - |
dc.identifier.eissn | 1432-0843 | - |
dc.identifier.pmid | 18026677 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs00280-007-0508-6 | - |
dc.subject.keyword | Paclitaxel | - |
dc.subject.keyword | Advanced gastric cancer | - |
dc.subject.keyword | 5-FU | - |
dc.subject.keyword | Leucovorin | - |
dc.contributor.alternativeName | Noh, Sung Hoon | - |
dc.contributor.alternativeName | Roh, Jae Kyung | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.alternativeName | Yoo, Nae Choon | - |
dc.contributor.alternativeName | Im, Chong Kun | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.alternativeName | Jeung, Hei Cheul | - |
dc.contributor.affiliatedAuthor | Noh, Sung Hoon | - |
dc.contributor.affiliatedAuthor | Roh, Jae Kyung | - |
dc.contributor.affiliatedAuthor | Yoo, Nae Choon | - |
dc.contributor.affiliatedAuthor | Im, Chong Kun | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Jeung, Hei Cheul | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 61 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 315 | - |
dc.citation.endPage | 321 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.61(2) : 315-321, 2008 | - |
dc.identifier.rimsid | 46646 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.